CALIXAR’s technology allows clients to generate membrane protein targets and allowing for the discovery of new hits, leads or compounds with greater affinity and precision. We help you to better comprehend the mechanism of actions, enabling lead optimizations, and solving high-resolution structures or co-structures of membrane protein targets.
CALIXAR produces high-quality native membrane protein targets to facilitate small molecules (ligand) discovery by screening (Fragment-based Drug Discovery – FBDD) and by Structure-Based Drug Design (SBDD).
Our protein targets are congruous with all screening platforms: (High Throughput Screening, NMR, SPR, Mass Spectrometry, crystallography, cryo-EM)
In addition, CALIXAR provides a more immeasurable understanding of ligand/protein recognition and promotes the discovery of the mechanism of action (orthosteric vs allosteric).
CALIXAR’s technology sustains the structural and functional integrities of membrane protein targets providing accurate discovery of hits/leads/candidates with therapeutic potential.
Traditionally, drug discovery was performed with low-quality membrane protein targets due to low stability, inaccurate conformation (mutations, truncations), and assay incompatibilities (protein buffer conditions, protein stability).
However, CALIXAR delivers high-quality native, pure, stable and functional membrane protein targets compatible with all drug discovery proposes.
Our membrane proteins are ideal for drug discovery scientists such as Biochemists, Structural Biologists, Biophysicists, and Medicinal Chemists. Our technology is also made for Pharma, biotechs, and academics involved in FBDD, SBDD and/or hit to lead optimization.
The CALIXAR® platform uses patented technologies only possible for clients under specific arrangements (license, co-development, and service).
You can leverage CALIXAR’s proprietary technology as well as other best-in-class membrane protein technology not obtainable anywhere else on the market.